上海复星医药(集团)股份有限公司获悉,其联营公司复星安特金生物技术有限公司已向香港联合交易所有限公司提交了H股于主板上市的申请。
上海复星医药(集团)股份有限公司获悉,其联营公司复星安特金生物技术有限公司已向香港联合交易所有限公司提交了H股于主板上市的申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.